As　one　of　the　most　malignant　breast　cancer　types,　triple-negative　breast　cancer　(TNBC)　treatment　is　a　particularly　great　challenge　in　the　current　era　of　precision　medicine.　Due　to　the　limited　effectiveness　and　targeting　of　current　treatment　methods,　it　is　urgently　need　to　develop　an　effective　precision　strategy　to　combat　TNBC.　Herein,　a　novel　TNBC　targeted　molecular　drug　based　on　zinc(II)　phthalocyanine　(BF-Pc)　was　rationally　designed　by　conjugating　a　Pim-1　kinase　inhibitor　with　high　TNBC　selectivity.　In　our　in　vitro　investigation,　BF-Pc　not　only　exhibits　extremely　high　targeting　to　TNBC　cells　overexpressed　Pim-1　kinases,　but　also　shows　ultra-efficient　photocytotoxicity　toward　TNBC　cells　far　beyond　the　normal　cells.　Significantly,　BF-Pc-induced　PDT　can　obviously　suppress　TNBC　cell　migration　and　invasion.　The　proposed　manner　in　our　work　offers　a　promising　approach　to　combat　TNBC　effectively　and　precisely.